| __timestamp | Viridian Therapeutics, Inc. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3243000 | 18516000 |
| Thursday, January 1, 2015 | 2472000 | 34140000 |
| Friday, January 1, 2016 | 2548000 | 51872000 |
| Sunday, January 1, 2017 | 19623000 | 71772000 |
| Monday, January 1, 2018 | 30421000 | 97501000 |
| Tuesday, January 1, 2019 | 32793999 | 118590000 |
| Wednesday, January 1, 2020 | 28304000 | 169802000 |
| Friday, January 1, 2021 | 620000 | 7491000 |
| Saturday, January 1, 2022 | 755000 | 8799000 |
| Sunday, January 1, 2023 | 1322000 | 253598000 |
Unveiling the hidden dimensions of data
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis compares the cost of revenue for Xencor, Inc. and Viridian Therapeutics, Inc. over the past decade. Xencor, a leader in protein engineering, has seen its cost of revenue grow by over 1,200% from 2014 to 2023, peaking in 2023 with a staggering 253 million. In contrast, Viridian, focusing on rare diseases, experienced a more volatile journey, with costs fluctuating significantly, peaking in 2019 and then dropping sharply by 2021. This divergence highlights the contrasting business models and market strategies of these two companies. While Xencor's steady increase suggests a robust expansion strategy, Viridian's fluctuations may indicate strategic pivots or market challenges. Investors should consider these trends when evaluating potential opportunities in the biotech sector.
Cost of Revenue: Key Insights for GSK plc and Viridian Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Insmed Incorporated and Xencor, Inc.
Analyzing Cost of Revenue: BioMarin Pharmaceutical Inc. and Viridian Therapeutics, Inc.
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: HUTCHMED (China) Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
Geron Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Iovance Biotherapeutics, Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.